Replimune Group, Inc. - 8-K Filing
Replimune Group reported a net loss of $73.7 million for the fiscal fourth quarter ended March 31, 2026, and $313.9 million for the full year compared to losses of $74.1 million and $247.3 million in the prior year periods. The company had $268.9 million in cash as of March 31, 2026, down from $483.8 million a year earlier due to increased R&D spending related to advancing clinical programs ahead of potential commercialization for RP1 and RP2. (Items: 2.02 of this Current Report on Form 8-K, including Exhibit 99)
Tickers: $REPL